期刊
NANOMEDICINE
卷 14, 期 18, 页码 2423-2440出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2019-0074
关键词
combination therapy; IDO inhibition; immunogenic cell death; melanoma; tryptanthrin derivative
资金
- National Natural Science Foundation of China [31671017, 81872809]
- National Key Research and Development Program of China [2017YFA0205600]
- Beijing Natural Science Foundation [7162108]
Aim: We developed a polycaprolactone-based nanoparticle (NP) to encapsulate tryptanthrin derivative CY-1-4 and evaluated its antitumor efficacy. Materials & methods: CY-1-4 NPs were prepared and evaluated for their cytotoxicity and associated mechanisms, indoleamine 2,3-dioxygenase (IDO)-inhibitory ability, immunogenic cell death (ICD)-inducing ability and antitumor efficacy. Results: CY-1-4 NPs were 123 nm in size. In vitro experiments indicated that they could both induce ICD and inhibit IDO. In vivo studies indicated that a medium dose reduced 58% of the tumor burden in a B16-F10-bearing mouse model, decreased IDO expression in tumor tissues and regulated lymphocytes subsets in spleen and tumors. Conclusion: CY-1-4 is a potential antitumor candidate that could act as a single agent with combined functions of IDO inhibition and ICD induction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据